Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImClone/Bristol Aim To Expand Erbitux's Reach To Asia

This article was originally published in PharmAsia News

Executive Summary

ImClone and Bristol-Myers Squibb are attempting to make Erbitux (cetuximab) the first EGFR receptor-inhibiting monoclonal antibody to be available in Japan under a co-development and co-commercialization agreement with Merck KGaA announced Oct. 17
Advertisement

Related Content

Takeda Discontinues Involvement In Matuzumab After Phase II Failure
Takeda Discontinues Involvement In Matuzumab After Phase II Failure
Erbitux Approved As Monotherapy In Metastatic Colorectal Cancer Setting
Advertisement
UsernamePublicRestriction

Register

SC065704

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel